Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aevi Genomic Medicine Inc (NASDAQ:GNMX)

During the Trading Day
1.63 +0.09 / +5.84%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
1.65 +0.02 / +1.23%
Volume: 12.6K
Health Technology

Company Description

Aevi Genomic Medicine, Inc. is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Contact Information

Aevi Genomic Medicine, Inc.
435 Devon Park Drive
Wayne Pennsylvania 19087
P:(610) 254-4201
Investor Relations:



Other institutional33.86%
Individual stakeholders14.04%
Mutual fund holders11.97%

Top Executives

Michael F. ColaPresident, Chief Executive Officer & Director
Brian D. PiperChief Financial & Principal Accounting Officer
Garry Arthur NeilChief Scientific Officer